联合脏器切除治疗进展期胃癌28例临床分析

回顾性分析了 1995～ 1998年联合脏器切除术 2 8例进展期胃癌患者的临床资料。 18例根治性切除 ,10例姑息性切除。联合横结肠及系膜切除 6例 ,联合脾切除 10例 ,联合胰体尾脾切除 5例 ,联合胰体尾脾肝左外叶切除 2例 ,联合左肝部分切除 2例 ,联合胰体尾脾横结肠 3例。生存超过 5年的 4例 ,超过 3年的 7例 ,超过 1年的 14例。     

联合脏器切除治疗进展期癌28例临床分析

回顾性分析了1995－1998年联合脏器切除术28例进展期胃癌患者的临床资料。18例根治性切除，10例姑息性切除。联合横结肠及系膜切除6例，联合脾切除10例，联合胰体尾脾切除5例，联合胰体尾脾肝左外叶切除2例，联合左肝部分切除2例，联合胰体尾脾横结肠3例。生存超过5年 的4例，超过3年的7例，超过1年的14例。     

胃癌联合脾胰体尾切除术的远期疗效

目的;研究胃癌联合脾胰体尾切除病例术后的远期疗效。方法：统计５０例胃癌患者联合脾胰体尾切除病例５年生存率并与未行脾胰体尾切除的病例进行比较。结果：单纯胃癌根治术和胃癌联合脾胰体尾切除两组５年生存率无显著差异。结论：按肿块边缘距脾门的最近距离≤５．０ｃｍ,４ｓ组淋巴结疑有转移或冰冻证实有癌转移、肿块呈浸润性生长并接近脾门指征,行癌肿联合脾胰体尾切除,可有效清除脾门区转移淋巴结,本组患者的远期疗效接近     

全胃切除治疗胃癌68例临床分析

目的　总结全胃切除治疗胃癌的经验。方法　对 1970～ 1997年间全胃切除治疗胃癌 68例临床资料进行回顾性分析。结果　根治性全胃切除 5 7例 ,姑息性全胃切除 11例 ,合并胰、脾、横结肠、部分肝切除 18例。术后切口感染 4例 ,肺部感染 4例 ,胸腔积液 3例 ,膈下感染 2例 ,吻合口漏 2例 ,心肌梗塞 1例 ,粘连性肠梗阻 1例 ,手术死亡 3例。术后 1、3、5年生存率分别为 72 .3 % ,40 .4%和 19.6%。结论　严格掌握手术适应症 ,恰当地选择切口 ,合理确定淋巴清除范围和联合脏器切除 ,选用最佳的消化道重建方式 ,避免吻合口漏 ,重视并存病的治疗均是影响全胃切除治疗胃癌疗效的重要因素。     

联合脏器切除治疗晚期贲门癌

目的　通过对 16例晚期贲门癌的临床追踪分析 ,以探讨其手术指征和疗效。方法　 1988年 3月至 1996年 6月对 16例贲门癌由于与其它脏器粘连浸润而行联合脏器切除 ,其中贲门癌合并肝左外叶切除 4例 ,合并脾切除 2例 ,合并胰体尾、脾切除 10例。结果　全组无手术死亡 ,无吻合口瘘 ,术后并发症发生率为 18.8% ( 3 / 16) ,均治愈 ,根治性切除 1、3、5年生存率分别为 5 0 %、2 5 %、12 .5 % ,姑息性切除均在半年内死亡。结论　贲门癌粘连浸润其它脏器应争取根治性切除 ,不能根治性切除者 ,应尽量避免进行复合脏器切除     

全胃切除治疗胃癌的临床体会

作者对５４例胃癌行全胃切除作了手术总结分析。男４４例，女１４例。本组全胃切除占同期胃癌手术的１３．８％，５年生存率２０．３％。根治切除的５年生存率为３４．８％。术后并发症为１２．９％，手术死亡率３．７％。着重对胃癌手术中全胃切除的合理应用、手术径路、脾胰体尾的联合切除，消化道重建等方面进行了讨论。全胃切除是胃癌治疗中一个重要的手段。     

关于胃癌的联合脏器切除——介绍保留胰的手术术式

胃癌的浸润、转移形式有4种:①直接浸润;②血行转移;③腹膜播种;④淋巴结转移。手术的目的是解决直接浸润,如胃癌向胰、横结肠、肝等周围脏器的S_3浸润,尤其是CM部癌向胰、膈、后腹膜的浸润机会较多。因血行转移而行联合脏器切除的对象只限于肝的孤立转移结节,肝的多发转移不是手术的适应证。对于腹膜播种是手术刀解     

32例进展期胃癌联合脏器切除临床分析

目的：探讨进展期胃癌手术治疗中联合脏器切除的可行性。方法：回顾性分析我科自1998年-2000年施行多脏器联合切除治疗的中、晚期胃癌患者的临床资料，其中肉眼下根治性手术切除23例，姑息性切除9例。对手术治疗结果进行分析。结果：术后无严重并发症，无手术死亡的病例。除1例失访外，其余31例经门诊和电话随访。随访5年后，其1、3、5年生存率分别为53．13％（17／32）、28．13％（9／32）、21．88％（7／32）。结论：联合脏器切除用于进展期胃癌的治疗是可行的，能延长患者生存时间；加强围手术期管理，不会明显增加手术并发症。因此，只要情况许可，联合脏器切除仍应作为进展期胃癌局部浸润转移首选的治疗方式。     

胃癌根治术中联合脏器切除的问题

外科根治性手术治疗是目前唯一能治愈胃癌的措施,为了达到根治目的,常常需联合脏器切除,如脾、胰、肝、横结肠、十二直肠、肾脏等,其中胰腺、脾脏、肝脏是最多见被联合切除的器官.随着外科手术技术的提高、先进仪器的应用、围手术期监护的发展手术切除率和生存率在不断提高,联合器官切除日益受到重视其指征也愈来愈受到关注.     

结肠癌并器官联合切除11例临床体会

结肠癌侵犯邻近器官多属中晚期,一般认为已失去根治机会,多予姑息处理或放弃手术。笔者对11例结肠不同部位癌行原发灶并受侵器官联合切除,获得较好的效果,现报告如下。1　临床资料本组11例,男7例,女4例,年龄41～78岁,术前确诊10例,其中1例术前诊断十二指肠不全性梗阻,剖腹探查术中发现系结肠肝曲部癌浸润所致。原发癌位于右半结肠4例,左半结肠5例,横结肠中部2例。并联合切除的器官:右肝叶部分切除2例,胆囊切除1例,十二指肠部分切除2例,右肾切除1例,全脾切除2例,胰尾切除1例,小肠部分切除2例,左侧卵巢切除1例,子宫全切1例,两个以上器官的切除…     

End results of simultaneous pancreatectomy, splenectomy and total gastrectomy for patients with gastric carcinoma.

A distal pancreatectomy is often performed simultaneously with splenectomy and total gastrectomy in the treatment of gastric carcinoma to facilitate dissection of the lymph nodes around the splenic artery. However, the morbidity of partial pancreatectomy is high. Patients undergoing pancreaticosplenectomy in conjunction with total gastrectomy are subject to leaks from the pancreatic stump, which may cause further complications. We performed a retrospective analysis to evaluate the end results of simultaneous distal pancreatectomy with total gastrectomy. The effect of distal pancreatectomy on survival was studied by examination of the records of 174 patients who underwent splenectomy and total gastrectomy for gastric carcinoma. Of these, 93 underwent distal pancreatectomy. Prognostic factors were determined and were examined in relation to the post-operative complications. There was no significant difference in the 5-year survival of the patients who did or did not undergo distal pancreatectomy. There was no correlation between any prognostic factor and distal pancreatectomy. In contrast, distal pancreatectomy was independently associated with post-operative complications. In this retrospective study, the addition of distal pancreatectomy to splenectomy at total gastrectomy for patients with gastric cancer did not affect survival but was associated with severe complications.     

新辅助化疗对进展期胃癌手术疗效的影响

目的 探讨新辅助化疗对进展期胃癌手术安全性的影响及近期疗效分析。方法 收集2012年3月至2016年3月广西医科大学附属肿瘤医院收治的Ⅲ期胃癌患者138例,行新辅助化疗50例（观察组）,直接手术治疗88例（对照组）,比较分析两组手术并发症的发生情况及近期疗效。结果 观察组和对照组术中输血、中转开腹、术中出血量、手术时间及淋巴结转移差异具有统计学意义（P＜0.05）,联合脏器切除率差异无统计学意义（P＞0.05）,术后主要并发症发生率比较差异亦无统计学意义（30.0%　vs　17.0%,P＞0.05）;单因素分析显示手术时间、出血量、新辅助化疗、术前化疗方案及周期等与术后并发症发生无关（P＞0.05）。观察组中位生存时间为36.9个月,对照组为30.9个月,两组生存曲线比较差异无统计学意义（P=0.317）;手术根治率差异有统计学意义（84.0% vs 68.2%,P=0.042）,术后12个月复发率差异亦有统计学意义（34.0% vs 52.3%,P=0.038）。结论 新辅助化疗不是影响胃癌术后并发症发生的因素,同时可提高进展期胃癌的根治性切除率,降低术后近期复发率,是一种安全有效的治疗手段。     

进展期胃癌新辅助化疗的临床疗效观察

目的 评价进展期胃癌新辅助化疗的疗效及对预后的影响.方法 回顾性分析45例确诊进展期胃癌患者通过新辅助化疗后再行手术治疗的疗效及预后,并与60例同期收治的未经新辅助化疗的胃癌手术患者进行对照.结果 新辅助化疗组临床有效率RR(CR+ PR)为68.9％ (31/45),其中CR 6.7％(3例),PR62.2％ (28例),SD 28.9％(13例),PD 2.2％(1例),术后1例在病理水平达到完全缓解(pCR),缓解率为2.2％ (1/45).不良反应主要为Ⅰ及Ⅱ度白细胞减少、恶心、脱发、呕吐及黏膜炎,其中Ⅲ及Ⅳ级的白细胞减少及胃肠道反应6例(13.3％),无严重感染和死亡病例.新辅助化疗组手术根治性切除率为84.4％,对照组的手术根治性切除率为66.7％,两者差异有统计学意义(P＜0.05).与对照组比较,新辅助化疗组的术后生存期明显延长(P＜0.05),且两组术后并发症无明显差异.结论 手术切除较为困难或根治率低的局部晚期胃癌患者,术前配合新辅助化疗,可显著提高胃癌切除率,并且最终可明显提高胃癌患者的术后生存期.     

Neoadjuvant Chemo-Radiation Using IGRT in Patients with Locally Advanced Gastric Cancer

The goal of this study was to see how effective and safe neoadjuvant chemoradiation with image-guided IMRT was in patients with locally advanced resectable gastric cancer. Between January 2013 and June 2019, patients with locally advanced (cT3/cT4 or N+) gastric cancer treated with neoadjuvant chemoradiotherapy at PUMCH (Peking Union Medical College Hospital) were retrospectively studied. Using concurrent chemotherapy (Capecitabine alone or XELOX*2 cycles), radiotherapy (IMRT (intensity-modulated radiation therapy) 45 Gy, 25#, 5 weeks) was delivered with IGRT (image-guided radiotherapy) before the start of each weeks therapy to ensure accuracy and repeatability. A total of 95 patients were enrolled in the study, 93 (97.9%) stage cT3/T4 and 85 (89.5%) stage N+. Of these, 85 patients (89.5%) had a tumor located in the upper 1/3 of the stomach, and 93/95 patients (97.9%) completed neoadjuvant chemoradiation, with 80 patients (84.2%) undergoing stomach resection (58 D2 and 22 D1 gastrostomies). Pathology downstaging was found in 68 patients (85.0%), with 66 patients (82.5%) receiving T downstaging and 56 patients (70.0%) receiving N downstaging. There were 11 individuals (13.8%) who had a pathological complete response (PCR). The average period of follow-up was 44.7 months (19–96 months). The 5-year OS (overall survival), LRFS (local recurrence-free survival), and DMFS (distant metastasis free survival) rates of patients were 47.0% (95% CI: 38.6–55.4), 86.55% (95% CI: 79.1–93.99) and 60.71% (95% CI: 51.49–69.93%), respectively. Thirteen (13.7%) patients had grade 3–4 leukopenia, anemia, and thrombocytopenia, while 9 (9.5%) patients had grade 3–4 anemia, and 5 (5.3%) patients had grade 3–4 thrombocytopenia. PCR was found to be a significant predictive factor for OS in multivariate analysis (HR = 11.211, 95% CI: 1.500–83.813, p = 0.024). The method of using IGRT image-guided IMRT (45 Gy, 25 fractions, 5 weeks) combined with concurrent chemotherapy in patients with locally advanced resectable gastric cancer was equally effective when compared to the clinical efficacy of neoadjuvant chemoradiotherapy, with clinical outcomes achieving equal efficacy, with similar PCR rates and high rates of OS, LRFS, and DMFS, as well as good tolerances of concurrent chemoradiotherapy with acceptable side effects.     

Validity of neoadjuvant chemotherapy with docetaxel,cisplatin, and S-1 for resectable locally advanced gastric cancer

Gastrectomy with D2 lymphadenectomy plus postoperative chemotherapy is the standard treatment for resectable locally advanced gastric cancer in Japan. However, the prognosis of patients with serosa-positive tumors remains unsatisfactory because of peritoneal recurrence. This study aimed to investigate the validity of neoadjuvant therapy with docetaxel, cisplatin, and S-1 (DCS) in patients with locally advanced gastric cancer. Thirty patients with locally advanced gastric cancer underwent neoadjuvant DCS therapy at Dokkyo Medical University Hospital between June 2013 and October 2015. Gastrectomy and D2 lymphadenectomy were performed after two cycles of preoperative DCS therapy. The clinical responses of the primary gastric tumors based on endoscopic findings were partial response in 17 patients (57%) and stable disease in 13 patients (43%). Analysis of pathological response in the primary gastric lesions showed grade 1a in five patients (17%), grade 1b in nine patients (30%), grade 2 in 11 patients (37%), and grade 3 in five patients (17%). Twenty-four patients (80%) remained alive after a median follow-up period of 31 months. The 2- and 3-year overall survival rates in all patients were 89 and 70%, respectively. The 2-year overall survival rate in pathological responders (grade 1b-3) was 96%, compared with 50% in pathological non-responders (grade 1a) (P = 0.00187). Pathological responders had a significantly higher survival rate than non-responders. These results indicate that neoadjuvant DCS therapy may improve the prognosis in patients with serosa-positive locally advanced gastric cancer.     

Clinical study on neoadjuvant chemoradiotherapy with S-l and cisplatin for locally advanced gastric carcinoma

Objective To investigate the efficacy and safety of neoadjuvant chemoradiotherapy with S-l and cisplatin in locally advanced gastric carcinoma patients. Methods From January 2009 to June 2012, a total of 62 gastric carcinoma patients were enrolled. The chemotherapy regimen consisted of two cycle of S-l (60 mg/m2, oral administration on day 1st-14th) and cisplatin (60 mg/m2, intravenous infusion on day 1st). Radiotherapy was also performed with a total dose of 45 Gy delivered at 1.8 Gy/ fraction, 5 fractions per week. Radical surgery was performed 3 weeks after chemoradiotherapy. Results All 62 patients completed the neoadjuvant radiotherapy, and 57 patients among them completed the neoadjuvant chemotherapy. 57 patients underwent surgery. Neoadjuvant chemoradiotherapy led to a clinical response rate of 69.4 % (43/62), and side effects were mostly grade I or II . The resection rate and radical resection (R0 resection) rate were 93.0 % (53/57) and 82.5 % (47/57), respectively, and the pathological response rate and PCR rate were 82.5 % (47/ 57) and 8.8 % (5/57), respectively. There was no postoperative death, besides, the postoperative complication rate was 15.8 % (9/57). The 1- , 2-, and 3-year overall survival rates were 80.7 % (46/57), 63.2 % (36/57) and 45.6 % (26/57), local and regional recurrence-free survival rates were 82.5 % (47/57), 66.7 % (38/57) and 50.9 % (29/57), and distant metastasis-free survival rates were 86.0 % (49/57), 68.4 % (39/57) and 59.6 % (34/57), respectively. Conclusion The neoadjuvant chemoradiotherapy with S-l and cisplatin combined with intensity modulated radiotherapy have a favorable effect for the treatment of locally advanced gastric carcinoma, which can promote the Ro resection rate and prolong the survival time with low postoperative complications.     

保留脾脏胃癌根治术临床疗效的荟萃分析

目的 探讨胃癌根治术中保留脾脏与切除脾脏的术后并发症及5年生存率情况。方法 计算机检索Pubmed、EMABSE、CBM、维普、万方及中国知网数据库,检索时间截止至2014年2月,收集关于胃癌根治术中保留脾脏与切除脾脏的术后并发症及5年生存率的研究,由2名评价者按照纳入和排除标准独立选择文献、提取资料、评价质量,采用STATA 110软件进行分析,计算合并OR值及其95％CI并行敏感性分析和发表偏倚评估。结果 最终纳入16篇文献,包括1949例切除脾脏患者（切除组）和2864例保留脾脏患者（保留组）。纳入文献的结果在术后并发症发生率和5年生存率的比较模型中均无异质性。各模型Meta分析结果显示：胃癌根治术中切除组的并发症发生率高于保留组,差异有统计学意义（OR=1.699,95％ CI： 1.436～2.009）;且切除组的5年生存率低于保留组,差异亦有统计学意义（OR=0.402,95％ CI： 0.363～0.445）。结论 胃癌根治术中保留脾脏可降低术后并发症的发生,同时能提高患者生存率。     

Study of the Value of Combined Multiorgan Resection in Surgical Treatment of Carcinoma of the Gastric Cardia

OBJECTIVE:To determine the value of resection of combined visceral organs in surgical treatment of gastric cardiac carcinoma. METHODS:We retrospectively analyzed 217 random patients with car- cinoma of the gastric cardia who underwent a gastric cardiac resection.The patients had been treated as fol ows:186 with partial gastrectomy,31 with total gastrectomy,97 with a combined-visceral resection,of which 82 under- went a splenectomy plus partial pancreatectomy,10 with splenectomy alone and 5 with partial hepatectomy and diaphragmatectomy. RESULTS:The total patients were divided into 3 groups:128 with a gas- trectomy alone,10 with gastrectomy and splenectomy,and 82 with gastrec- tomy and splenectomy plus pancreatectomy.The operating times for these 3 groups were respectively 3.0 h,3.1 h and 3.8 h.The hospitalization times were respectively 23.8 d,31.2 d and 25.9 d.No differences in post-operative complications were found between these 3 groups.There were 92 patients who underwent a gastrectomy combined with a splenectomy and(or)the pancreatectomy,in which 92 No.10 lymph nodes were eliminated,with an average of one in each patient.Among the 125 patients not receiving a sple- nectomy but with elimination of lymph nodes,82 underwent a gastrectomy combined with partial pancreatectomy,of which 107 lymph nodes were elimi- nated for the No.11 group,with an average of 1.3 in each patient.There was a statisticaly significant difference between the 2 groups.The overal survival rates were similar in the 3 groups showing no statistical differences, but was higher in the Stage III patients with a combined resection of multi- organs.For patients in the Stage IV without resection of multi-organs,the survival rate was higher,but there was no significant difference between the 2 groups. CONCLUSION:It is difficult to determine precisely the involvement of para-tumorous organs with the eye during an operation.Combining a sple- nectomy with a pancreatectomy does not increase the post-operative compli- cations following surgical treatment for carcinoma of the gastric cardia.The combination of a splenectomy and partial pancreatectomy results in a higher survival rate and has an important significance for eliminating the lymph nodes of group 10 and 11,especially for patients in Stage III.In the applica- tion of a resection combining multi-organs,the doctor should make every effort to decrease the trauma and the complications based on the condition that the cancerous tissue is totally resected.     

腹腔镜结直肠癌根治术与同期开腹手术的回顾性研究

目的回顾性分析比较腹腔镜结直肠癌根治术与同期开腹手术患者的临床资料,探讨应用腹腔镜技术行结直肠癌根治术的可行性。方法 2004年8月至2009年4月腹腔镜辅助下结直肠手术184例,右半结肠癌根治术37例,横结肠癌根治术11例,左半结肠癌根治术31例,直肠癌Dixon手术53例、Miles手术49例、Hartmann手术3例;开腹结直肠癌根治术患者718例（开腹组）,其中右半结肠癌根治术107例,横结肠癌根治术54例,左半结肠癌根治术131例,直肠癌Dixon手术288例、Miles手术117例、Hartmann手术21例,对照比较两组患者的手术及术后情况。结果两组均无术中、术后严重并发症和手术死亡病例,腹腔镜组有4例中转开腹手术。腹腔镜组与开腹组的平均手术时间分别为（210.5±26.5）min和（95.5±12.5）min,差异有显著性（P〈0.05）。腹腔镜组术中失血量明显少于开腹组〔（85.5±12.5）ml比（200.5±22.5）ml,P〈0.05〕。清除的淋巴结数量,直肠前切除肿瘤远端切缘长度两组间差异无显著性。腹腔镜组术后胃肠功能恢复时间明显早于开腹组〔进食时间：（4.5±0.5）d比（5.5±0.5）d,P〈0.05）。腹腔镜组住院时间明显短于开腹组〔（9.5±0.5）d比（12.5±0.5）d,P〈0.05〕。两组的3,5年生存率比较差异无显著性（89.8%比89.7%,P〉0.05;75.5%比74.5%,P〉0.05）。结论腹腔镜结直肠癌切除术安全、有效,具有可行性。     

局部晚期食管鳞癌单纯手术与术后辅助放化疗的临床研究

目的 评价局部晚期食管鳞癌单纯手术与术后辅助放化疗的疗效和安全性。方法 分析 2008～2011年收治的术后经病理证实的局部晚期食管鳞癌患者214例,其中单纯手术93例（单纯手术组）,术后调强放疗联合替吉奥化疗121例（术后放化疗组）,比较两组的不良反应、局部复发率、远处转移率及生存率。结果 单纯手术组和术后放化疗组局部复发率分别为45.37%和27.38%（P＜0.05）,远处转移率分别为46.23%和31.65%（P＜0.05）;1年、3年、5年生存率分别为90%、55%、23%和98%、74%、52%（P＜0.05）,中位生存期分别为41.7个月和64.6个月（P<0.05）。术后放化疗组不良反应以1~3级为主,3级主要为白细胞下降、放射性食管炎和咳嗽,晚期不良反应为放射性肺纤维化和吻合口狭窄。结论  局部晚期食管鳞癌根治术后调强放疗联合替吉奥化疗安全、可行,能有效提高生存率。